Predictors of hospitalization for HIV-positive women and men drug users, 1996-2000

Public Health Reports

Volumn 117, Issue SUPPL. 1, 2002, Pages

  Schoenbaum, Ellie E ^a   Lo, Yungtai ^a   Floris Moore, Michelle ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIRETROVIRUS AGENT; DIAMORPHINE; METHADONE; NARCOTIC AGENT;

ADULT; ARTICLE; CAUCASIAN; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG ABUSE; ETHNIC DIFFERENCE; ETHNIC GROUP; FEMALE; HEROIN DEPENDENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; NARCOTIC DEPENDENCE; NEGRO; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE;

ADULT; AFRICAN AMERICANS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH SERVICES ACCESSIBILITY; HISPANIC AMERICANS; HIV INFECTIONS; HOSPITALIZATION; HOSPITALS, URBAN; HUMANS; MALE; MIDDLE AGED; NEW YORK CITY; RISK FACTORS; SEX FACTORS; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; WOMEN'S HEALTH;

EID: 0036432195     PISSN: 00333549     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Waidmann TA, Rajan S. Race and ethnic disparities in health care access and utilization: An examination of state variation. Med Care Res Rev 2000;57:(Suppl 1)55-84.
2. Centers for Disease Control and Prevention. HIV and AIDS cases reported through December 2000, United States. HIV/AIDS Surveillance Rep 2000;12:5-10.
3. Bassetti S, Battegay M, Furrer H, Rickenbach M, Flepp M, Kaiser L, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? J Acquir Immune Defic Syndr 1999;21:114-9.
4. Murri R, Fantoni M, Del Borgo C, Izzi I, Visona R, Suter F, et al. Intravenous drug use, relationship with providers, and stage of HIV disease influence the prescription rates of protease inhibitors. J Acquir Immune Defic Syndr 1999;22:461-6.
5. Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman JF, et al. Variations in the care of HIV-infected adults in the United States. JAMA 1999;281:2305-15.
6. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998;280:1497-503.
7. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7.
8. Bing EG, Kilbourne AM, Brooks RA, Lazarus EF, Senak M. Protease inhibitor use among a community sample of people with HIV disease. J Acquir Immune Defic Syndr 1999;20:474-80.
9. Markson LE, Houchens R, Fanning TR, Turner BJ. Repeated emergency department use by HIV-infected persons: Effect of clinic accessibility and expertise in HIV care. J Acquir Immune Defic Syndr 1998;17:35-41.
10. Turner BJ, Zhang D, Laine C, Pomerantz RJ, Cosler L, Hauck WW. Association of provider and patient characteristics with HIV-infected women's antiretroviral therapy regimen. J Acquir Immune Defic Syndr 2001;27:20-9.
11. Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, et al. Time to initiate highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001;5:1707-15.
12. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998;280:544-6.
13. McCullagh P, Nelder JA. Generalized Linear Models. New York: Chapman Hall; 1989.
14. Gebo KA, Diener-West M, Moore RD. Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:143-52.
15. Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel F, et al. A comparison of exposure groups in the EuroSIDA study: Starting highly active antiretroviral therapy (HAART), response to HAART and survival. J Acquir Immune Defic Syndr 1999;22:369-78.
16. Weber AE, Yip B, O'Shaughnessy MV, Montaner JS, Hogg RS. Determinants of hospital admission among HIV-positive people in British Columbia. CMAJ 2000;162:783-6.
17. Palepu A, Tyndall MW, Leon H, Muller J, O'Shaughnessy MV, Schechter MT, et al. Hospital utilization and costs in a cohort of injection drug users. CMAJ 2001;165:415-20.
18. Selwyn PA, Alcabes PA, Hartel DM, Buono D, Schoenbaum EE, Klein RS, et al. Clinical manifestations and predictors of disease progression in injecting drug users with human immunodeficiency virus infection. N Engl J Med 1992;327:1697-1703.
19. Tashima KT, Hogan JW, Gardner LI, Korkontzelou C, Schoenbaum EE, Schuman P, et al. A longitudinal analysis of hospitalization and emergency department use among human immunodeficiency virus-infected women reporting protease inhibitor use. Clin Infect Dis 2001;33:2055-60.
20. Mouton Y, Alfandari S, Valette M, Cartier F, Dellamonica P, Humbert G, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997;11:F101-5.
21. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clin Infect Dis 2001;33:1417-23.
22. Strathdee SA, Palepu A, Cornelisse PGA, Yip B, O'Shaughnessy MV, Montaner JS, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998;280:547-9.
23. Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Good MJD. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retrovir 2002;17:1467-71.
24. Schaubel DE, Stewart DE, Morrison HI, Zimmerman DL, Cameron JI, Jeffery JJ, et al. Sex inequality in kidney transplantation rates. Arch Intern Med 2000;160:2349-54.
25. Vakili BA, Kaplan RC, Brown DL. Gender-based differences in early mortality of patients undergoing primary angioplasty for first acute myocardial infarction. Circulation 2001;104:3034-8.